Document:

Exhibit 10.1

 

SECOND
AMENDMENT TO

SENIOR
CONVERTIBLE NOTE Purchase Agreement

 

April 13, 2020

 

This Amendment to Convertible Note Purchase
Agreement (this “Amendment”) is entered into as of the date first written above by and among Coherus BioSciences, Inc.,
a Delaware corporation (the “Company”) and the undersigned holders (each a “Holder” and collectively,
the “Holders”) that are parties to that certain Senior Convertible Note Purchase Agreement, dated as of February 29,
2016, by and among the Company and the holders named therein (as amended, the “Note Purchase Agreement”). Capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Note Purchase Agreement.

 

RECITALS

 

WHEREAS, pursuant
to Section 13.01 of the Note Purchase Agreement, any term of the Note Purchase Agreement may be amended with the written consent
of the Company, the Guarantors and each Holder affected thereby.

 

WHEREAS, any
waiver or amendment effected in accordance with Section 13.01 of the Note Purchase Agreement shall be binding upon each party
to the Note Purchase Agreement and each Holder (including each future Holder, regardless of whether such future Holder is a party
hereto).

 

NOW THEREFORE BE
IT RESOLVED, that the Note Purchase Agreement is hereby amended pursuant to Section 13.01 of the Note Purchase Agreement
as follows:

 

ARTICLE I.

 

AMENDMENT

 

The definition of Restricted
Payment in Section 1.01 of the Note Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“Restricted
Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to
any Equity Interest in the Company or its Subsidiaries, or any payment (whether in cash, securities or other property),
including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation
or termination of any such Equity Interest of the Company or its Subsidiaries; provided, however, that the following
will not constitute a Restricted Payment: (a) a dividend, distribution or payment consisting solely of, or made solely
with the net cash proceeds of a substantially concurrent sale of, Equity Interests of the Company (other than Disqualified
Capital Stock); (b) the repurchase of any Equity Interests deemed to occur upon the exercise of stock options or similar
instruments to the extent such Equity Interests represent a portion of the exercise price of such stock options or interests;
(c) the payment of cash in lieu of issuing or delivering any fractional share of Common Stock or other Equity Interest;
(d) any Dividend or distribution by a Subsidiary of the Company on its Equity Interests; (e) any payment (including
premium) to a counterparty under a Permitted Bond Hedge Transaction in accordance with the definition thereof; and
(f) any other dividend, distribution or payment that does not exceed fifteen million dollars ($15,000,000) in the
aggregate since the date of this Agreement.

 

    1

     

    

 

Section 1.01 of
the Note Purchase Agreement is hereby amended by adding the following defined term:

 

“Permitted Bond Hedge Transaction”
means any call or capped call option (or substantively equivalent derivative transaction) relating to the Common Stock (or other
securities or property following a merger event or other change of the Common Stock) purchased by the Issuer in connection with
the issuance of any Indebtedness by the Issuer that is convertible into or exchangeable for Common Stock; provided, that, the purchase
price for such Permitted Bond Hedge Transaction does not exceed the net cash proceeds received by the Issuer from the issuance
of such Indebtedness in connection with such Permitted Bond Hedge Transaction.

 

Article ii.

CONDITIONS TO EFFECTIVENESS

 

This Amendment shall
be effective as of the date hereof upon the Company having received the duly executed signatures page of this Amendment from
each of the parties hereto.

 

ARTICLE III.

Acknowledgement and Consent

 

Each of the parties hereto hereby acknowledges
that he has reviewed the terms and provisions of the Note Purchase Agreement and this Amendment and consents to the amendment of
the Note Purchase Agreement effected pursuant to this Amendment.

 

ARTICLE IV.

Miscellaneous

 

Section 4.1     Notes.
Each certificate representing any Note issued pursuant to the Note Purchase Agreement on or after the date of this Amendment will
contain terms that are consistent with this Amendment.

 

Section 4.2     Headings.
Section and Subsection headings in this Amendment are included herein for convenience of reference only and shall not constitute
a part of this Amendment for any other purpose or be given any substantive effect.

 

Section 4.3     Governing
Law. This Amendment shall be governed by and construed and interpreted under the laws of the State of New York.

 

Section 4.4     Execution
in Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute
one and the same instrument, and each of the parties hereto may execute this Agreement by signing any such counterpart. A facsimile
or electronic mail transmission of this Amendment bearing a signature on behalf of a party hereto shall be legal and binding on
such party.

 

[SIGNATURE PAGE FOLLOWS]

 

    2

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Amendment as of the day and year first above written.

 

	 	
        COHERUS BIOSCIENCES, INC.

        as the Company

	 	 
	 	By:	/s/ Dennis M. Lanfear
	 	Name:	Dennis M. Lanfear
	 	Title:	Chief Executive Officer

 

	 	
        Coherus Intermediate
        Corp.

        as a Guarantor

	 	 
	 	By:	/s/ Dennis M. Lanfear
	 	Name:	Dennis M. Lanfear
	 	Title:	Chief Executive Officer

 

	 	Intekrin Therapeutics Inc.
	 	as a Guarantor
	 	 
	 	By:	/s/ Dennis M. Lanfear
	 	Name:	Dennis M. Lanfear
	 	Title:	Chief Executive Officer

 

Signature
Page to the 

Second Amendment to Senior Convertible Note Purchase Agreement

 

     

     

    

 

	 	
        Healthcare Royalty
        Partners III, L.P.

        as a Holder

         

        By: Healthcare Royalty GP III, LLC, its general partner

	 	 
	 	By:	/s/ Clarke B. Futch
	 	Name:	 Clarke B. Futch
	 	Title:	Managing Partner

 

Signature
Page to the

Second
Amendment to Senior Convertible Note Purchase Agreement

 

     

     

    

 

	 	
        KKR Biosimilar L.P.

        as a Holder

         

        By: KKR Biosimilar GP LLC,

its General Partner

	 	 
	 	By:	/s/ Ali Satvat
	 	Name:	 Ali Satvat
	 	Title:	Partner

 

Signature
Page to the

Second
Amendment to Senior Convertible Note Purchase AgreementExhibit 10.2

 

FIRST AMENDMENT TO CREDIT AGREEMENT

  

THIS FIRST AMENDMENT
TO CREDIT AGREEMENT (this “Amendment”), dated as of April 13, 2020 (the “Amendment Effective
Date”), is made among COHERUS BIOSCIENCES, INC., a Delaware corporation (the “Borrower”),
HCR COLLATERAL MANAGEMENT, LLC, as administrative agent (in such capacity, “Administrative Agent”) and the Lenders
signatory hereto representing the Required Lenders.

 

Borrower, the Lenders
and Administrative Agent are parties to a Credit Agreement dated as of January 7, 2019 (as amended, restated or modified
from time to time, the “Loan Agreement”). Borrower has requested that the Required Lenders agree to certain
amendments to the Loan Agreement. The Required Lenders have agreed to such request, subject to the terms and conditions hereof.

 

Accordingly, the parties
hereto agree as follows:

 

SECTION 1     Definitions;
Interpretation.

 

(a)            Terms
Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise
defined herein shall have the meanings assigned to them in the Loan Agreement.

 

(b)            Interpretation.
The rules of interpretation set forth in Section 1.02 of the Loan Agreement shall be applicable to this Amendment and
are incorporated herein by this reference.

 

SECTION 2     Amendment
to the Loan Agreement. Section 8.03(h)(vi) of the Loan Agreement is hereby amended and restated in its entirety as
follows:

 

“(vi) immediately
after giving effect to the incurrence of any Convertible Bond Indebtedness, the aggregate outstanding amount of all Convertible
Bond Indebtedness (excluding, for the avoidance of doubt, the Existing Convertible Notes) shall not exceed the greater of (x) $230,000,000
and (y) twenty percent (20%) of the Borrower’s Market Capitalization as of the date of pricing for such Convertible
Bond Indebtedness,”

 

SECTION 3     Miscellaneous.

 

(a)            References
Within Loan Agreement. Each reference in the Loan Agreement to “this Agreement” and the words “hereof,”
 “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan Agreement as
amended by this Amendment.

 

(b)            Binding
Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

 

(c)            Governing
Law. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK.

 

(d)            Severability
of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of
any provision.

 

(e)            Counterparts.
This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart
of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will
be as effective as delivery of a manually executed counterpart hereof.

 

    1

     

    

 

(f)            Loan
Documents. This Amendment and the documents related thereto shall constitute Loan Documents.

 

(g)            Electronic
Execution of Certain Other Documents. The words “execution,” “execute”, “signed,” “signature,”
and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated
hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic
signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative
Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability
as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided
for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State
Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

  

[Balance of Page Intentionally Left
Blank; Signature Pages Follow]

 

    2

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Amendment, as of the date first above written.

  

	BORROWER:	COHERUS BIOSCIENCES, INC.,

a Delaware corporation
	 	 
	 	By:	/s/ Dennis Lanfear
	 	Name: Dennis Lanfear
	 	Title: President and Chief Executive Officer

 

[Signature
Page to First Amendment to Credit Agreement]

 

    3

     

    

	 
	 
	Acknowledged and agreed:
	 
	ADMINISTRATIVE AGENT:	HCR Collateral Management, LLC
	 
	 	By:	 /s/ Clarke B. Futch
	 	Name: Clarke B. Futch
 Title: Managing Partner

 

[Signature
Page to First Amendment to Credit Agreement]

 

    4

     

    

 

 

	 LENDERS:	HEALTHCARE ROYALTY PARTNERS III, L.P.,

a Delaware limited partnership
	 	 
	 	 By: HealthCare Royalty GP III, LLC, its general partner
	 	 
	 	By:	/s/ Clarke B. Futch
	 	Name: Clarke B. Futch
 Title: Managing Partner
	 	 
	 	 HCRP OVERFLOW FUND, L.P.,
	 	 a Delaware limited partnership
	 	 
	 	 By: HCRP Overflow GP, LLC, its general partner
	 	 
	 	By:	/s/ Clarke B. Futch
	 	Name: Clarke B. Futch
 Title: Managing Partner
	 	 
	 	 MOLAG HEALTHCARE ROYALTY, LLC,
	 	 a Delaware limited liability company
	 	 
	 	By:	/s/ Clarke B. Futch
	 	Name: Clarke B. Futch
 Title: Managing Partner

 

[Signature
Page to First Amendment to Credit Agreement]

 

    5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]